gasguide

Carboprost (Hemabate)

Hemabate · 15-methyl PGF2α

Synthetic prostaglandin F2α analog (uterotonic)

15-methylated synthetic analog of prostaglandin F2α. Binds prostaglandin F receptors on uterine smooth muscle → potent contraction. Also constricts pulmonary smooth muscle → BRONCHOSPASM (contraindication in asthma).

Indications

  • Postpartum hemorrhage from uterine atony — third-line after oxytocin + methylergonovine
  • Termination of pregnancy (off-label use in some institutions)

Dosing

ContextAdultPediatric
Postpartum hemorrhage250 mcg IM (or IM into uterine wall by surgeon) q15 min, max 8 doses (2 mg total)

Pharmacokinetics

Onset 5-15 min IM. Half-life ~3 h. Hepatic + renal metabolism.

Hemodynamic effects

↑BP (modest), ↑PVR (significant — pulmonary vasoconstriction), tachycardia.

Respiratory effects

BRONCHOSPASM — common (~10% incidence) — CONTRAINDICATED in asthma.

Side effects

  • !Nausea + vomiting (~50%) — pre-treat with antiemetic
  • !Diarrhea (~50%)
  • !Bronchospasm — CONTRAINDICATED in asthma (use misoprostol instead)
  • !Pulmonary HTN exacerbation
  • !Fever, chills
  • !Increased intracranial pressure

Contraindications

  • ×Asthma (absolute)
  • ×Active pulmonary disease
  • ×Hypersensitivity
  • ×Active cardiac/renal/hepatic disease (relative)

Clinical pearls

  • PPH stepwise: oxytocin → methylergonovine → CARBOPROST → misoprostol → mechanical/surgical (Bakri balloon, B-Lynch, embolization, hysterectomy).
  • ASTHMA — major contraindication. Use MISOPROSTOL (PGE1) instead — does not cause bronchospasm.
  • Pre-treat with ANTIEMETIC (ondansetron 4 mg + dexamethasone 4-8 mg) — N/V universal.
  • May be given INTRA-MYOMETRIALLY by surgeon (transabdominal injection into uterine wall) — direct effect, less systemic.
  • Plus TXA 1 g IV (WOMAN trial — reduces death from PPH bleeding).
Education only — confirm against current package inserts and institutional protocols. Doses assume normal organ function unless otherwise noted.